Literature DB >> 425965

Small airways in progressive systemic sclerosis (PSS).

R D Bjerke, D P Tashkin, P J Clements, S K Chopra, H Gong, M Bein.   

Abstract

Obstructive disease involving peripheral airways has been noted in diffuse interstitial pulmonary disease, including sarcoidosis and cryptogenic fibrosing alveolitis. The possibility of obstruction of small airways in progressive systemic sclerosis (PSS) has been suggested by widespread bronchiolectasis and peribronchial fibrosis noted at necropsy. We performed pulmonary function studies in 39 subjects (22 nonsmokers and 17 smokers) with PSS, most of whom had functional evidence of interstitial pulmonary involvement (increased static recoil pressure and reduced diffusing capacity). The 1 second forced expiratory volume to forced vital capacity ratio (FEV1:FVC) was normal in all subjects. Although the severity of the restrictive process was greater in nonsmokers compared with that in smokers, the maximal mid-expiratory flow rate, closing volume, closing capacity, volume of isoflow, change in maximal expiratory flow at 50 per cent of vital capacity during 80 per cent helium--20 per cent oxygen breathing compared with air breathing (delta Vmax50), ratio of dynamic to static lung compliance at different breathing frequencies and upstream airway conductance at static recoil pressures of 5 and 10 cm H2O were nearly always normal in the nonsmokers but were frequently abnormal in the smokers with PSS. These findings suggest that diffuse interstitial pulmonary disease due to PSS generally does not lead to functional evidence of obstruction in peripheral airways and that when the latter is found it can likely be attributed to the effects of concomitant cigarette smoking.

Entities:  

Mesh:

Year:  1979        PMID: 425965     DOI: 10.1016/0002-9343(79)90528-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

1.  Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.

Authors:  Anagha A Divekar; Dinesh Khanna; Fereidoun Abtin; Paul Maranian; Rajeev Saggar; Rajan Saggar; Daniel E Furst; Ram Raj Singh
Journal:  Clin Immunol       Date:  2011-09-05       Impact factor: 3.969

2.  Clinical characteristics associated with small airways disease in systemic sclerosis.

Authors:  Sanskriti Varma; Jae Hee Yun; John S Kim; Anna J Podolanczuk; Nina M Patel; Elana J Bernstein
Journal:  J Scleroderma Relat Disord       Date:  2022-03-20

3.  The disconnect between visual assessment of air trapping and lung physiology for assessment of small airway disease in scleroderma-related interstitial lung disease: An observation from the Scleroderma Lung Study II Cohort.

Authors:  Sangmee Sharon Bae; Lila Pourzand; Grace Hyun Kim; Bianca E Villegas; Andrea Oh; Daniel E Furst; Jonathan Goldin; Donald P Tashkin
Journal:  J Scleroderma Relat Disord       Date:  2021-10-23

Review 4.  Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics.

Authors:  Anna Kowalska-Kępczyńska
Journal:  J Clin Med       Date:  2022-04-20       Impact factor: 4.964

Review 5.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

6.  Patterns of pulmonary function in smoking and nonsmoking patients with progressive systemic sclerosis.

Authors:  Silvia A Quadrelli; Luciana Molinari; Lorena M Ciallella; Martin Bosio; Alejandro Salvado
Journal:  Rheumatol Int       Date:  2009-01-08       Impact factor: 2.631

7.  Scleroderma lung disease.

Authors:  Jérôme Le Pavec; David Launay; Stephen C Mathai; Paul M Hassoun; Marc Humbert
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

8.  High resolution computed tomography in systemic sclerosis. Real diagnostic utilities in the assessment of pulmonary involvement and comparison with other modalities of lung investigation.

Authors:  A Pignone; M Matucci-Cerinic; A Lombardi; R Fedi; R Fargnoli; R De Dominicis; M Cagnoni
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

Review 9.  Bronchiolitis obliterans.

Authors:  T E King
Journal:  Lung       Date:  1989       Impact factor: 2.584

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.